CIK 0001631574 · Large accelerated filer
Wave Life Sciences, Inc.
Sign in to watch- Ticker
- WVE
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- Phone
- 617-949-2900
- Business address
- 733 CONCORD AVENUE, CAMBRIDGE, MA, 02138
- Former names
- Wave Life Sciences Ltd., Wave Life Sciences LTD., WAVE Life Sciences Ltd., Wave Life Sciences Pte Ltd
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-08-11 | TAKANASHI KEN Director | Sale 10b5-1 | −3,864 | $6.01 | $23K | 20,079 |
| 2026-08-11 | Tan Aik Na Director | Sale 10b5-1 | −432 | $6.01 | $3K | 24,968 |
| 2026-03-30 | RA CAPITAL MANAGEMENT, L.P. Director | Purchase | +971,091 | $6.50 | $6.3M | 26,975,505 |
| 2026-03-27 | RA CAPITAL MANAGEMENT, L.P. Director | Purchase | +2,495,623 | $6.43 | $16.0M | 26,004,414 |
| 2026-03-26 | RA CAPITAL MANAGEMENT, L.P. Director | Purchase | +4,954,558 | $6.06 | $30.0M | 23,157,567 |
| 2026-03-26 | RA CAPITAL MANAGEMENT, L.P. Director | Purchase | +351,224 | $6.38 | $2.2M | 23,508,791 |
| 2026-03-23 | TAKANASHI KEN Director | Conversion | +3,901,348 | 9,606,408 | ||
| 2026-03-23 | TAKANASHI KEN Director | Conversion · Series A Preferred Shares | −3,901,348 | 0 | ||
| 2026-02-26 | Francis Chris See Remarks | Option exercise 10b5-1 | +17,900 | $3.87 | $69K | 79,767 |
| 2026-02-26 | Francis Chris See Remarks | Sale 10b5-1 | −17,900 | $15.09 | $270K | 61,867 |
| 2026-02-26 | Francis Chris See Remarks | Option exercise 10b5-1 | +15,294 | $4.75 | $73K | 77,161 |
| 2026-02-26 | Francis Chris See Remarks | Sale 10b5-1 | −15,294 | $15.00 | $229K | 61,867 |
| 2026-02-26 | Francis Chris See Remarks | Option exercise · Share Option (right to buy) 10b5-1 | −17,900 | 143,200 | ||
| 2026-02-26 | Francis Chris See Remarks | Option exercise · Share Option (right to buy) 10b5-1 | −15,294 | 61,175 | ||
| 2026-02-09 | Moran Kyle Chief Financial Officer | Sale | −3,588 | $13.45 | $48K | 134,385 |
| 2026-02-09 | BOLNO PAUL President and CEO | Sale | −10,480 | $13.45 | $141K | 275,520 |
| 2026-02-09 | Francis Chris See Remarks | Sale | −1,883 | $13.45 | $25K | 61,867 |
| 2026-02-09 | Vargeese Chandra See Remarks | Sale | −3,228 | $13.45 | $43K | 408,246 |
| 2026-02-05 | Moran Kyle Chief Financial Officer | Grant or award | +45,625 | 137,973 | ||
| 2026-02-05 | Moran Kyle Chief Financial Officer | Grant or award · Share Option (right to buy) | +273,750 | 273,750 |
Page 2 of 13 · 255 trades